Key Events at ACC 2009
Sunday, March 29, 2009
|
| |
Oral Presentations
|
10:30AM - 12:00PM
Orange County Convention Center,
Room
W414D
|
INTERVENTIONAL PHARMACOLOGY: “Impact of Different Antithrombotic
Regimens on Ischemic and Hemorrhagic Outcomes Following Percutaneous Coronary Intervention
in Elderly: Pooled Analysis from the REPLACE-2, ACUITY and HORIZONS-AMI Trials”
(Nikolsky, et al.)
|
| |
11:30AM - 11:42AM
Orange County Convention Center,
Room
W414D |
INTERVENTIONAL PHARMACOLOGY: “Impact of Gastrointestinal
Bleeding on Outcomes of Patients Treated With Contemporary Antithrombotic Strategies:
Pooled Analysis From 3 Randomized Trials” (Nikolsky, et al.) |
| |
2:00PM - 3:30 PM
Orange County Convention Center,
Room
W414D |
COMPLEX PATIENTS: “Impact of PCI vs. CABG on the Development
of Acute Renal Failure in Patients With Acute Coronary Syndromes: Insights From
the ACUITY Trial” (Weisz, et al.)
|
3:30PM - 4:30 PM
Orange County Convention Center,
West
Hall D
|
PCI – DIABETES: “Clinical and Angiographic Predictors of
Death or Myocardial Infarction in Diabetics with Acute Coronary Syndromes Undergoing
Percutaneous Coronary Intervention: An ACUITY Subanalysis” (Goto, et al.)
|
| |
|
|
PCI – DIABETES: “Outcomes of patients with diabetes mellitus
undergoing PCI treated with bivalirudin versus heparin plus a glycoprotein IIb/IIIa
inhibitor: Pooled analysis from the REPLACE-2, ACUITY and HORIZONS-AMI Trials”
(Feit, et al.) |
| |
|
|
PCI – DIABETES: “Late Outcomes of Patients with Diabetes
Mellitus and Acute Myocardial Infarction Undergoing Primary Angioplasty: One Year
Results from The HORIZONS AMI trial” (Witzenbichler, et al.)
|
| |
|
|
PCI – RENAL INSUFFICIENCY: “Bivalirudin Therapy Reduces 30-Day
Bleeding Complications in Patients with Chronic Renal Insufficiency: A Pooled Analysis
of the REPLACE-2, ACUITY, and HORIZONS Trials” (Mehran, et al.)
|
| |
|
|
PCI – RENAL INSUFFICIENCY: “Contrast-Induced Nephropathy
Occurs Frequently and is a Powerful Independent Predictor of Morbidity and Mortality
In Patients With Acute Myocardial Infarction Undergoing Primary PCI” (Weisz,
et al.)
|
| |
|
|
INTERVENTIONAL OUTCOMES: “Achieving Door to Balloon Times
of Less Than 90 Minutes for STEMI Patients Transferred for Primary PCI”
(Ahmed,
et al.)
|
| |
|
|
INTERVENTIONAL OUTCOMES: “Outcomes of Patients with Acute
Coronary Syndromes and Non-obstructive Coronary Artery Disease: Analysis from the
Randomized ACUITY Trial” (Nikolsky, et al.)
|
| |
Monday, March 30, 2009
|
| |
Oral Presentations
|
10:30AM - 12:00 PM
Orange County Convention Center,
Room
W314B |
AMI: “Impact of Chronic Kidney Disease on One-Year Outcomes
of Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty: Results
From the HORIZONS AMI Trial” (Mehran, et al.) |
9:30 AM - 10:30 AM
Orange County Convention Center,
West
Hall D |
PCI – ACUTE MI: “Prognostic Utility of TIMI Flow After PrimaryPCI
in Acute Myocardial Infarction: Insights from the HORIZONS-AMI Trial”
(Caixeta,
et al.) |
| |
|
|
PCI – ACUTE MI: “Impact of Clopidogrel Loading Dose on the
Effectiveness of Bivalirudin in Primary Angioplasty for Acute Myocardial Infarction:
The HORIZONS-AMI Trial” (Dangas, et al.) |
| |
|
|
PCI – ACUTE MI: “Impact of Gender on the Safety and Effectiveness
of Bivalirudin in Patients with Acute Myocardial Infarction Undergoing Primary Angioplasty:
The Horizons-AMI” (Grinfeld, et al.) |
| |
|
|
PCI – ACUTE MI: “Bivalirudin Therapy Reduces 30 Day Bleeding
Complications in Women Undergoing PCI for Acute Coronary Syndrome: Results of the
REPLACE-2, ACUITY and HORIZONS Pooled Analysis” (Lansky, et al.) |
| |
|
|
PCI – ACUTE MI: “Clinical and Angiographic Risk Score to
Predict Ischemic Outcomes at 1 Year in Acute Coronary Syndromes: The ACUITY Risk
Score” (Lansky, et al.) |
| |
|
|
PCI – ACUTE MI: “Late Outcomes of Elderly Patients with Acute
Myocardial Infarction Undergoing Primary Angioplasty: One Year Results from the
HORIZONS-AMI Trial” (Dudek, et al.) |
| |
|
|
PCI – ACUTE MI: “Impact of Bivalirudin Monotherapy on 30-day
Outcomes in Patients with Acute Coronary Syndromes and Complex Coronary Stenoses
Undergoing Percutaneous Coronary Intervention” (Goto, et al.) |
| |
|
|
INTERVENTIONAL PHARMACOLOGY: “Impact of Vascular Closure
Devices and Antithrombotic/Antiplatelet Therapy on Access Site Bleeding. Insights
from the Acuity Trial” (Sanborn, et al.) |
|
Safety Considerations
ANGIOMAX with provisional use of glycoprotein IIb/IIIa inhibitor is indicated for
use as an anticoagulant in patients undergoing percutaneous coronary intervention
(PCI), and in patients with or at risk for heparin-induced thrombocytopenia and
thrombosis syndrome (HIT/HITTS) undergoing PCI. ANGIOMAX is intended for use with
aspirin and has been studied only in patients receiving concomitant aspirin. ANGIOMAX
is contraindicated in patients with active major bleeding or hypersensitivity to
ANGIOMAX or its components. The most common (≥10%) adverse events for ANGIOMAX were back pain, pain, nausea, headache,
and hypotension. An unexplained fall in blood pressure or hematocrit, or any unexplained
symptom, should lead to serious consideration of a hemorrhagic event and cessation
of ANGIOMAX administration. Please see complete prescribing information.